Oncology Biosimilars Market to Grow at 29.87% CAGR to 2018

Oncology Biosimilars Market to Grow at 29.87% CAGR to 2018

ReportsnReports.com adds Global Oncology Biosimilars Market 2014-2018 industry research report of 71 pages to the life science intelligence collection of its online library. According to this report, global oncology biosimilars market is forecast to grow at a CAGR of 29.87 percent over the period 2013-2018. Complete report is available at http://www.reportsnreports.com/reports/317863-global-oncology-biosimilars-market-2014-2018.html .

This report covers the present scenario and the growth prospects of the Global Oncology Biosimilars market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales biosimilars used in cancer treatment. Biosimilars are follow-on versions of biological medicines that are developed after the expiry of the patent protection on the original product. Biosimilar medicines have a mechanism of action that is similar to that of the original biological medicines. Though biosimilars have many similarities to the innovator product, they are not an exact copy of the reference biopharmaceutical product. Currently, biosimilars are being incorporated into oncology treatment practices. The biosimilars used in oncology in the supportive care setting are known as oncology biosimilars.

The Global Oncology Biosimilars Market 2014-2018 research report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Oncology Biosimilars market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Increased numbers of patent expirations are driving the oncology biosimilars market growth. Since biosimilars are follow-on versions of original biological medicines and can be made only after the patent protection of the original product expires, these expirations open up opportunities for many biosimilars companies to enter the market.  One of the major challenges faced by the industry is the risks related to drug failure. Outsourcing of biosimilars manufacturing is a trend observed which may help push profitability in the industry. Contract research manufacturers and CROs in countries like India and China are set to benefit because of this trend, which creates a win-win situation for all stakeholders of the industry.

Companies like Biocon, Celltrion, Dr. Reddy's Laboratories, Hospira, Mylan, Sandoz, 3SBio, Abbvie, AstraZeneca, BioXpress Therapeutics, Boehringer Ingelheim, Coherus Biosciences, Intas Pharmaceuticals, Merck Serono, Pfizer and Wockhardt are discussed in this research on oncology biosimilars market available for purchase at http://www.reportsnreports.com/Purchase.aspx?name=317863